绥美凯很伤肝肾吗

The main ingredient of Suimeikai (Doted Abalamid Tablets) is Doptabalamid. This product is a film-coated tablet that appears white or off-white after the coating is removed. This product should be taken under the guidance of a physician with experience in HIV infection. SuimeiKai can be taken with or without food. Suimeike (dolute abalamide tablets) is suitable for the treatment of adults and adolescents over 12 years old (with a weight of at least 40kg) infected with human immunodeficiency virus (HIV). Today we will learn more about whether Suimeikai hurts the liver and kidneys?

The main ingredient of Suimeikai (Dolute abalamide tablets) is Dolute abalamide, which is currently a good drug for the treatment of human immunodeficiency virus. Although the drug is very effective, it is recommended that patients who require long-term medication need to regularly check their liver function. Once it is found that the liver is burdened by medication, further combined medication treatment is required under the guidance of a doctor, or the medication needs to be changed to continue treatment.

Geriatric Patients There are limited data on the use of dolutegravir, abacavir, and lamivudine in patients aged ≥65 years, and there is no evidence that older patients require different doses than younger adult patients. Taking into account age-related changes, such as decreased renal function and changes in hematological parameters, special caution is recommended when using Trimax in this age group.

Patients with renal impairment whose creatinine clearance is less than 50 mL/min are not recommended to take Suimeikai (Doteta abalamide tablets).

Hepatic Impairment Abacavir is primarily metabolized by the liver. There are no clinical data in patients with moderate or severe hepatic impairment; therefore, the use of Trimax (doluteabalamide) is not recommended unless deemed necessary. For patients with mild hepatic impairment (Child-Pugh score 5-6), close monitoring is required, including monitoring of abacavir plasma levels if feasible.

Suimeike (dolute abalamide tablets) is suitable for the treatment of adults and adolescents over 12 years old (with a weight of at least 40kg) infected with human immunodeficiency virus (HIV). HIV-infected patients, regardless of race, should be screened for the HLA-B*5701 allele before starting treatment with abacavir-containing products. If the patient is known to carry the RLA-B*5701 allele, he should not take products containing abacavir.

The above is the content of the precautions for Suimeikai (Doteta Abalamid Tablets), I hope it can help you!